FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2252912453> ?p ?o ?g. }

• W2252912453 endingPage "20509" @default.
• W2252912453 startingPage "20509" @default.
• W2252912453 abstract "20509 Background: High grade STS is expected to benefit from dose-dense doxorubicin/ifosfamide (doxo/ifo) sequential chemotherapy. This trial was designed using the two-stage Minimax design, in which 6 responses were needed among the first 19 pts to proceed to the second stage of the trial (a=0.05, β=0.20) to detect a 20% difference in RR as compared to expected 30%. Preliminary results of the first 20 pts are presented. Patients and Methods: Eligible pts had untreated, metastatic or locally advanced, high-grade STS, > 5 cm; age 18- 60 y; ECOG-PS 0–2; normal cardiac, renal and hepatic function; and signed informed consent. Pts were treated with doxo 30 mg/m 2 /d, D1–3, every 14 d, 3 cycles, followed by ifo 2.5 g/m 2 /d, D1–5, every 21 d, 3 cycles, with mesna and G-CSF support. Results: 20 pts were enrolled (7 in the neo-adjuvant setting with curative intent, 13 palliative). Median age: 39y (23–60); 5 synovial, 5 leiomyo, 4 sarcoma NOS, 2 MFH, 4 others. Primary site: 11 lower extremity; mean tumor size 13 cm. Median number of cycles was 3 for both drugs. 12 pts completed all planned chemotherapy cycles, and the mean relative dose intensity was 92±15% and 89±16% for doxo and ifo, respectively. Anemia was the most frequent toxicity (18 pts). 75 cycles were administered and grade 3/4 toxicities (CTC NCI 2.0) were observed in 27. G3 neutropenia was observed in 4 pts, none fatal. Thromboembolic events occurred in 4 pts (2 DVT, 2 PE). One pt presented a LVEF drop from 60% to 34% and developed symptomatic cardiac failure. Among 10 evaluable pts who completed chemotherapy, no response (CR or PR) was observed; eight pts had stable and 2 progressive disease. Surgery was performed in 6 pts, 4 of them limb-sparing, without changing the previous surgical plan. None of these pts presented complete pathologic response, with rate of necrosis ranging from 0–60%. At a median follow-up of 6 mo (1–16), 6 pts had died: 4 of disease progression, one sudden death (unknown cause) after 2 wks from the last chemotherapy cycle, and one patient died from pulmonary embolism. Conclusion: Sequential high-dose doxorubicin followed by ifosfamide failed in demonstrating any response in high grade STS, in addition to an unacceptable toxicity profile. Results of overall survival are pending. No significant financial relationships to disclose." @default.
• W2252912453 created "2016-06-24" @default.
• W2252912453 creator A5006054106 @default.
• W2252912453 creator A5026541010 @default.
• W2252912453 creator A5029262451 @default.
• W2252912453 creator A5041386593 @default.
• W2252912453 creator A5042668003 @default.
• W2252912453 creator A5071945361 @default.
• W2252912453 creator A5085449385 @default.
• W2252912453 date "2007-06-20" @default.
• W2252912453 modified "2023-09-26" @default.
• W2252912453 title "Phase II prospective study of dose-dense doxorubucin and ifosfamide in high-grade, locally advanced or metastatic soft tissue sarcoma (STS) patients" @default.
• W2252912453 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.20509" @default.
• W2252912453 hasPublicationYear "2007" @default.
• W2252912453 type Work @default.
• W2252912453 sameAs 2252912453 @default.
• W2252912453 citedByCount "1" @default.
• W2252912453 crossrefType "journal-article" @default.
• W2252912453 hasAuthorship W2252912453A5006054106 @default.
• W2252912453 hasAuthorship W2252912453A5026541010 @default.
• W2252912453 hasAuthorship W2252912453A5029262451 @default.
• W2252912453 hasAuthorship W2252912453A5041386593 @default.
• W2252912453 hasAuthorship W2252912453A5042668003 @default.
• W2252912453 hasAuthorship W2252912453A5071945361 @default.
• W2252912453 hasAuthorship W2252912453A5085449385 @default.
• W2252912453 hasConcept C126322002 @default.
• W2252912453 hasConcept C126894567 @default.
• W2252912453 hasConcept C141071460 @default.
• W2252912453 hasConcept C142724271 @default.
• W2252912453 hasConcept C2776694085 @default.
• W2252912453 hasConcept C2777063308 @default.
• W2252912453 hasConcept C2777506904 @default.
• W2252912453 hasConcept C2778119113 @default.
• W2252912453 hasConcept C2778256501 @default.
• W2252912453 hasConcept C2778629024 @default.
• W2252912453 hasConcept C2778850193 @default.
• W2252912453 hasConcept C2780376820 @default.
• W2252912453 hasConcept C71924100 @default.
• W2252912453 hasConcept C90924648 @default.
• W2252912453 hasConceptScore W2252912453C126322002 @default.
• W2252912453 hasConceptScore W2252912453C126894567 @default.
• W2252912453 hasConceptScore W2252912453C141071460 @default.
• W2252912453 hasConceptScore W2252912453C142724271 @default.
• W2252912453 hasConceptScore W2252912453C2776694085 @default.
• W2252912453 hasConceptScore W2252912453C2777063308 @default.
• W2252912453 hasConceptScore W2252912453C2777506904 @default.
• W2252912453 hasConceptScore W2252912453C2778119113 @default.
• W2252912453 hasConceptScore W2252912453C2778256501 @default.
• W2252912453 hasConceptScore W2252912453C2778629024 @default.
• W2252912453 hasConceptScore W2252912453C2778850193 @default.
• W2252912453 hasConceptScore W2252912453C2780376820 @default.
• W2252912453 hasConceptScore W2252912453C71924100 @default.
• W2252912453 hasConceptScore W2252912453C90924648 @default.
• W2252912453 hasIssue "18_suppl" @default.
• W2252912453 hasLocation W22529124531 @default.
• W2252912453 hasOpenAccess W2252912453 @default.
• W2252912453 hasPrimaryLocation W22529124531 @default.
• W2252912453 hasRelatedWork W1946636618 @default.
• W2252912453 hasRelatedWork W2002246400 @default.
• W2252912453 hasRelatedWork W2013258557 @default.
• W2252912453 hasRelatedWork W2123895550 @default.
• W2252912453 hasRelatedWork W2145828205 @default.
• W2252912453 hasRelatedWork W2319511185 @default.
• W2252912453 hasRelatedWork W2354646688 @default.
• W2252912453 hasRelatedWork W2403018570 @default.
• W2252912453 hasRelatedWork W2412134406 @default.
• W2252912453 hasRelatedWork W2428528889 @default.
• W2252912453 hasVolume "25" @default.
• W2252912453 isParatext "false" @default.
• W2252912453 isRetracted "false" @default.
• W2252912453 magId "2252912453" @default.
• W2252912453 workType "article" @default.